Professional ResourcesTerms of Use and Privacy Policy
Legal notice
Daiichi Sankyo, Inc. ("Daiichi Sankyo") maintains this site for your personal information, education, and communication. While you are free to browse the site, your access to and use of the site is subject to the following terms and conditions ("Terms and Conditions") and all applicable laws. By accessing and browsing the site, you accept, without limitation or qualification, the Terms and Conditions.
Terms and conditions
Copyrights and Trademarks
The contents of this site are protected under applicable copyright and trademark laws. Except as otherwise set forth on the website, all images and text are owned by or licensed to Daiichi Sankyo and, except as provided within these Terms and Conditions, may not be downloaded, distributed, stored, reused, reposted, modified, or otherwise used without the express written permission of Daiichi Sankyo. Daiichi Sankyo neither warrants nor represents that your use of material displayed on the site will not infringe rights of third parties.
Noncommercial Use
You may print a single copy of the content for your own personal, non-commercial use, provided you also retain all copyright and other proprietary notices contained in the materials or as specified on the site. The further use, re-use, copying, distribution, redistribution, modification, publication, or re-posting of or to any part of this site (including the text, images, audio, and video) is strictly prohibited and nothing contained on this site should be construed as granting, by implication, estoppel, or otherwise, any license or right to use any Daiichi Sankyo intellectual property right (including, but not limited to any patent, trademark, trade name, copyright, or trade secret).
Special Note Regarding Website Use By Children
The website is neither directed at nor designed for use by children (ie, anyone under 18 years old).
Disclaimer
This site is controlled and operated from the United States. The information on this site is designed to comply with the laws of the United States and is intended for use by US residents only. Daiichi Sankyo makes no representation that materials in this site are appropriate or applicable for use in other countries. The information provided on this site is for general educational and informational purposes only. Such information is not meant to be a substitute for advice provided by a physician or other qualified healthcare professional. PLEASE CONSULT WITH YOUR DOCTOR OR OTHER HEALTHCARE PROFESSIONAL BEFORE USING ANY DRUG PRODUCT DISCUSSED WITHIN THIS SITE.
While Daiichi Sankyo uses reasonable care to ensure that information is accurate at the time it is added on this site, the contents of this site are provided to you "AS IS," WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT and Daiichi Sankyo makes no representations as to the availability, accuracy, or completeness of the content of this site. Daiichi Sankyo may make changes to these materials at any time, without notice, and makes no commitment to update the information contained herein. Daiichi Sankyo shall not be liable for any damages or injury resulting from your access to, or inability to access, this site or from your reliance on any information at this site or for any viruses that may infect your computer equipment or other property on account of your access to, use of, or browsing in this site or your downloading of any materials, data, text, images, video, or audio from this site.
Links to Other Sites
Our site may provide links or references to other websites not affiliated with Daiichi Sankyo. Daiichi Sankyo believes its links provide helpful information; however, Daiichi Sankyo is not responsible for the content of such other sites and shall not be liable for any damages or injury arising from your access to such sites. Links to other sites are provided only as a convenience to users of our site.
Collection and Use of Your Personal Information
Daiichi Sankyo may collect data from you that you provide to us voluntarily such as your name, postal address, email address, telephone number, and other personal information. The information you provide is used to contact you, via email or by regular mail, to provide you with information that we believe may be of interest to you. We do not sell or transfer the information you send to us to others outside our company, except that your data may be transferred to various outside companies or agents working on behalf of Daiichi Sankyo to help fulfill business transactions and to Daiichi Sankyo's affiliates. However, Daiichi Sankyo will not share any of your personal information with third parties for their own marketing use unless you explicitly give us permission to do so.
Automatically Collected Information
Daiichi Sankyo automatically collects certain types of information whenever you interact with us on this site and in some emails we may send each other. Automatic technologies we use may include, for example, web server logs and IP addresses, cookies, and web beacons.
Web Server Logs and IP Addresses: An IP address is a unique identifying number that is automatically assigned to any computer connected to the Internet. Depending on the nature of your Internet connection, the IP address may change each time you connect or may always be the same number for that computer. Daiichi Sankyo reserves the right to log IP addresses for system administration, security, statistical analysis, demographic analysis of website use, and other functions.
Cookies: Cookies are text files that are stored on a website user's computer by the website. Cookies allow Daiichi Sankyo to help make your web experience better and to conduct website analysis and performance reviews of this site. Additionally, cookies can tell us how and when pages in a website are visited and by how many people. Most web browsers are set up to accept cookies, although you can reset your browser to refuse all cookies or to indicate when a cookie is being sent. Note, however, that some portions of our sites may not work properly if you refuse cookies.
Web Beacons: On certain web pages or emails, Daiichi Sankyo may utilize a common Internet technology called a "web beacon" (also known as an "action tag" or "clear GIF technology"). Web beacons help analyze the effectiveness of websites by measuring, for example, the number of visitors to a site or how many visitors clicked on key elements of a site.
Web beacons, cookies, and other tracking technologies do not automatically obtain personal information about you. Only if you voluntarily submit personal information, such as by registering or sending emails, can these automatic tracking technologies be used to provide further information about your use of the websites to improve their usefulness to you.
Public Forums
To the extent that this site makes forums, message boards and/or news groups available to you, please remember that any information that is disclosed in these areas becomes public information. You should exercise caution in disclosing personally identifying information there or in any other public section of the Internet.
Feedback and Suggestions
Daiichi Sankyo welcomes your feedback and suggestions about how to improve this site. Any ideas, suggestions, information, know-how, material, or other content (collectively, "content") received through this site, however, will be deemed to include a royalty-free, perpetual, irrevocable, transferable, worldwide, nonexclusive right and license for Daiichi Sankyo to adopt, publish, reproduce, disseminate, transmit, distribute, copy, use, modify, create derivative works, display, (in whole or part), or act on such content without additional approval or consideration, in any form, media, or technology now known or later developed for the full term of any rights that may exist in such content.
Revisions to These Terms and Conditions
Daiichi Sankyo may at any time revise these Terms and Conditions by updating this posting. You are bound by any such revisions and should therefore periodically visit this page to review the then current Terms and Conditions to which you are bound.
Email
Print
Help your patients save
Want to help your patients save
on their TRIBENZOR prescription?
With the Savings That Last card
patients pay no more than $25 a month
through 2016.*
INDICATIONS for BENICAR, BENICAR HCT, AZOR, and TRIBENZOR
BENICAR and BENICAR HCT are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. BENICAR HCT is not indicated for initial therapy.
AZOR and TRIBENZOR are indicated for the treatment of hypertension, to lower blood pressure. AZOR is indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals. AZOR can be used alone or with other antihypertensive agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which these drugs principally belong. There are no controlled trials demonstrating risk reduction with AZOR or TRIBENZOR.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.
Initial therapy with AZOR is not recommended in patients ≥75 years of age or in hepatically impaired patients.
TRIBENZOR is not indicated for the initial therapy of hypertension.
BENICAR, BENICAR HCT, and AZOR important safety information
WARNING: AVOID USE IN PREGNANCY
When pregnancy is detected, discontinue BENICAR, BENICAR HCT, or AZOR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. See WARNINGS AND PRECAUTIONS, Fetal/Neonatal Morbidity and Mortality.
Due to the olmesartan medoxomil component, BENICAR, BENICAR HCT, and AZOR have the following Warnings and Precautions:
Hypotension in Volume- or Salt-Depleted Patients
In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (eg, those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with BENICAR, BENICAR HCT, or AZOR. Treatment should start under close medical supervision.
Impaired Renal Function
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.
Non-Steroidal Anti-Inflammatory Agents
In patients who are elderly, volume-depleted (including those on diuretics), or with compromised renal function, co-administration of olmesartan medoxomil and NSAIDs, including COX-2 inhibitors, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in these patients. The antihypertensive effect of olmesartan medoxomil may be attenuated by NSAIDs, including COX-2 inhibitors.
The prescribing information for BENICAR HCT also includes the following warnings regarding its hydrochlorothiazide component:
BENICAR HCT is not recommended in patients with severe renal impairment. BENICAR HCT is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
Fetal/Neonatal Morbidity and Mortality
Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.
Hepatic Impairment
Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Hypersensitivity Reaction
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
Systemic Lupus Erythematosus
Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.
Acute Myopia and Secondary Angle-Closure Glaucoma
Thiazides can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Discontinue hydrochlorothiazide as rapidly as possible in these patients. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Lithium Interaction
Lithium generally should not be given with thiazides.
Due to the amlodipine component, AZOR has the following additional Warnings and Precautions:
Vasodilation
Since the vasodilation attributable to amlodipine in AZOR is gradual in onset, acute hypotension has rarely been reported after oral administration. Nonetheless, caution, as with any other peripheral vasodilator, should be exercised when administering AZOR, particularly in patients with severe aortic stenosis.
Severe Obstructive Coronary Artery Disease
Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase.
Hepatic Impairment
Since amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t1/2) is 56 hours in patients with severely impaired hepatic function, caution should be exercised when administering AZOR to patients with severe hepatic impairment. Initial therapy with AZOR is not recommended in hepatically impaired patients.
Effect of Amlodipine on Simvastatin
Due to increased exposure to simvastatin, if simvastatin is co-administered with amlodipine, do not exceed doses of greater than 20 mg daily of simvastatin.
Geriatric Use
Elderly patients have decreased clearance of amlodipine. Initial therapy with AZOR is not recommended in patients ≥75 years old.
Adverse Reactions
BENICAR/BENICAR HCT
The withdrawal rates due to adverse reactions were similar with BENICAR and BENICAR HCT to placebo: BENICAR (2.4% vs 2.7%); BENICAR HCT (2.0% vs 2.0%).
The incidence of adverse reactions with BENICAR and BENICAR HCT was similar to placebo.
- The only adverse reaction that occurred in >1% of patients treated with BENICAR and more frequently than placebo was dizziness (3% vs 1%)
- Adverse reactions reported in >2% of patients taking BENICAR HCT and more frequently than placebo included nausea (3% vs 0%), hyperuricemia (4% vs 2%), dizziness (9% vs 2%), and upper respiratory tract infection (7% vs 0%)
AZOR
The only adverse reaction that occurred in greater than or equal to 3% of patients treated with AZOR and more frequently than placebo was edema. The placebo-subtracted incidence was 5.7% (5/20 mg), 6.2% (5/40 mg), 13.3% (10/20 mg), and 11.2% (10/40 mg). The edema incidence for placebo was 12.3%.
Adverse reactions seen at lower rates but at about the same or greater incidence as in patients receiving placebo included hypotension, orthostatic hypotension, rash, pruritus, palpitation, urinary frequency, and nocturia.
In individual clinical trials of amlodipine and olmesartan medoxomil, other commonly reported adverse reactions included headache, dizziness, and flushing.
Laboratory Tests
There was a greater decrease in hemoglobin and hematocrit with AZOR compared to either component alone.
Dosage and Administration
No initial dosage adjustments are recommended with BENICAR in elderly or in moderate to marked renal impairment*/hepatic dysfunction.
- In patients with possible depletion of intravascular volume (eg, patients on diuretics, particularly with impaired renal function), BENICAR should be initiated under close medical supervision and consideration given to use of a lower starting dose
For BENICAR HCT, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range.
*Creatinine clearance <40 mL/min.
Please see full prescribing information for BENICAR, BENICAR HCT, and AZOR.
TRIBENZOR important safety information
WARNING: AVOID USE IN PREGNANCY
When pregnancy is detected, discontinue TRIBENZOR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. See WARNINGS AND PRECAUTIONS, Fetal/Neonatal Morbidity and Mortality.
Contraindications
TRIBENZOR is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
Hypotension in Volume- or Salt-Depleted Patients
In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients, symptomatic hypotension due particularly to the olmesartan component may occur after initiation of treatment with TRIBENZOR. Treatment should start under close medical supervision.
Increased Angina and Myocardial Infarction
Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy or at the time of dosage increase.
Impaired Renal Function
Avoid use in patients with severely impaired renal function (creatinine clearance ≤30 mL/min). If progressive
renal impairment becomes evident, consider withholding or discontinuing TRIBENZOR.
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum
creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil
in patients with unilateral or bilateral renal artery stenosis, but similar effects would be expected with TRIBENZOR
because of the olmesartan medoxomil component.
Thiazides may precipitate azotemia in patients with renal disease. Cumulative effects of the drug may develop in
patients with impaired renal function.
Hepatic Impairment
Avoid use in patients with severely impaired hepatic function.
Amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t1/2) is 56 hours in
patients with severely impaired hepatic function.
Minor alterations of fluid and electrolyte balance due to
hydrochlorothiazide may precipitate hepatic coma.
Electrolyte and Metabolic Imbalances
Due to the hydrochlorothiazide component, observe patients for clinical signs of fluid or electrolyte imbalance.
Hypersensitivity Reaction
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such history.
Systemic Lupus Erythematosus
Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.
Acute Myopia and Secondary Angle-Closure Glaucoma
Thiazides can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Discontinue hydrochlorothiazide as rapidly as possible in these patients. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Vasodilation
Although vasodilation attributable to amlodipine is gradual in onset, acute hypotension has rarely been reported after oral administration. Patients with severe aortic stenosis may be at particular risk.
Effect of Amlodipine on Simvastatin
Due to increased exposure to simvastatin, if simvastatin is co-administered with amlodipine, do not exceed doses of greater than 20 mg daily of simvastatin.
Non-Steroidal Anti-Inflammatory Agents
In patients who are elderly, volume-depleted (including those on diuretics), or with compromised renal function, co-administration of olmesartan medoxomil and NSAIDs, including COX-2 inhibitors, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in these patients. The antihypertensive effect of olmesartan medoxomil may be attenuated by NSAIDs, including COX-2 inhibitors.
Lithium Interaction
Lithium generally should not be given with thiazides.
Adverse Reactions
The most frequently reported adverse reaction was dizziness (5.8 to 8.9%). The other most frequent adverse reactions occurring in greater than or equal to 2% of patients treated with TRIBENZOR are peripheral edema (7.7%), headache (6.4%), fatigue (4.2%), nasopharyngitis (3.5%), muscle spasms (3.1%), nausea (3.0%), upper respiratory tract infection (2.8%), diarrhea (2.6%), urinary tract infection (2.4%), and joint swelling (2.1%).
Please see full prescribing information for TRIBENZOR.
Trademarks not owned by Daiichi Sankyo, Inc., are property of their respective owners.
